Spontaneously formed tumorigenic hybrids of Meth A sarcoma and macrophages grow faster and are better vascularized than the parental tumor.
Macrophages and Meth A sarcoma cells spontaneously fuse and give rise to tumorigenic hybrid cell lines with a mixed phenotype. We report here that the hybrid tumors grow faster and have a strikingly better developed vasculature than the parent sarcoma. Thus, electron microscopy and immunohistochemical analysis revealed that in the most active areas of neovascularization, the tumors that emerged from inocula of monoclonal hybrid cell populations had a microvessel density nearly twice that of Meth A tumors after 1 week of growth. Moreover, the proportion of vessels associated with pericytes, detected by staining for smooth muscle alpha-actin, was 3 times higher in the hybrid tumors, attesting to the more advanced differentiation of their vasculature. The collagenous stroma component was also more extensive in the hybrid tumors. Concentration of the angiogenic proteins vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta) were significantly higher in supernatants of hybrid cell cultures compared with Meth A cultures. These observations indicate that the growth advantage of the hybrid tumors over the parental sarcoma is due to a higher angiogenic capacity. Because the malignant features of many tumors correlate with angiogenesis and because macrophages are known to be major producers of angiogenic factors, our data open the possibility that the intense neovascularization of highly aggressive cancers in some cases reflects the acquisition of macrophage traits by heterotypic cell fusion.
Department of Clinical Pathology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway. ltbusund@tpg.com.au
Lill-Tove R
LT
Busund
Mette K
MK
Killie
Kristian
K
Bartnes
Rolf
R
Seljelid
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D016922:Cellular Senescence; D016228:Endothelial Growth Factors / Q000378:metabolism; D005260:Female; D006649:Histocompatibility Antigens / Q000032:analysis; D006822:Hybrid Cells / Q000473:pathology*; D008222:Lymphokines / Q000378:metabolism; D008264:Macrophages / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic; D010455:Peptides / Q000502:physiology; D012509:Sarcoma / Q000473:pathology* / Q000503:physiopathology; D016212:Transforming Growth Factor beta / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000951:Antigens, Neoplasm; D016228:Endothelial Growth Factors; D006649:Histocompatibility Antigens; D008222:Lymphokines; D010455:Peptides; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C029237:tumor-associated transplantation antigen